1. Home
  2. DCGO vs MNOV Comparison

DCGO vs MNOV Comparison

Compare DCGO & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DocGo Inc.

DCGO

DocGo Inc.

HOLD

Current Price

$0.52

Market Cap

65.5M

Sector

Health Care

ML Signal

HOLD

Logo Medicinova Inc

MNOV

Medicinova Inc

HOLD

Current Price

$1.50

Market Cap

66.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DCGO
MNOV
Founded
2015
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Managed Health Care
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.5M
66.9M
IPO Year
2020
2004

Fundamental Metrics

Financial Performance
Metric
DCGO
MNOV
Price
$0.52
$1.50
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
4
Target Price
$2.38
$7.50
AVG Volume (30 Days)
1.4M
53.5K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$322,196,000.00
$2,360,807.00
Revenue This Year
N/A
N/A
Revenue Next Year
$7.41
$180.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
194.15
52 Week Low
$0.52
$1.17
52 Week High
$2.45
$1.96

Technical Indicators

Market Signals
Indicator
DCGO
MNOV
Relative Strength Index (RSI) 35.07 54.33
Support Level N/A $1.40
Resistance Level $0.87 $1.60
Average True Range (ATR) 0.05 0.06
MACD -0.00 0.01
Stochastic Oscillator 2.54 58.03

Price Performance

Historical Comparison
DCGO
MNOV

About DCGO DocGo Inc.

DocGo Inc is a provider of last-mile mobile health services and integrated medical mobility solutions. The company uses its care delivery platform to provide mobile health services, virtual care management, and ambulance services. It has three reporting segments: Mobile Health Services, Transportation Services, and Corporate. A majority of its revenue is generated from the Mobile Health Services segment, which includes various healthcare services performed at homes, offices, and other locations and event services such as on-site healthcare support at sporting events and concerts. Geographically, the company generates a majority of its revenue from the United States and the rest from the United Kingdom.

About MNOV Medicinova Inc

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.

Share on Social Networks: